The European treatment of severe atopic eczema in children taskforce (TREAT) survey (pages 901–909)
L.E. Proudfoot, A.M. Powell, S. Ayis, S. Barbarot, E. Baselga Torres, M. Deleuran, R. Fölster-Holst, C. Gelmetti, A. Hernández-Martin, M.A. Middelkamp-Hup, A.P. Oranje, K. Logan, M. Perkins, A. Patrizi, G. Rovatti, O. Schofield, P. Spuls, Å. Svensson, C. Vestergaard, C.-F. Wahlgren, J. Schmitt, C. Flohr and in collaboration with the European Dermato-Epidemiology Network (EDEN)
Article first published online: 10 OCT 2013 | DOI: 10.1111/bjd.12505
What's already known about this topic?
- There is a paucity of evidence for the use of systemic agents in children with atopic eczema refractory to conventional therapy, resulting in considerable variation in patient management.
What does this study add?
- The TREAT survey is the first European venture investigating current practice in the use of systemic agents in severe childhood atopic eczema.
- The survey confirms significant variability in therapeutic approaches, although there are strong trends favouring a small number of agents, namely ciclosporin, oral corticosteroids and azathioprine.
Vol. 169, Issue 5, 1171, Article first published online: 31 OCT 2013